Wearable Cardio Defib for Cardiac/Circ Problem: 64.2% of denials overturned
In 53 California IMR decisions from 2019 to 2025, reviewers overturned 34 (64.2%). In the last five years: 68.4% of 38. 7 were medical-necessity disputes, 46 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 6 | 66.7% |
| 2022 | 7 | 57.1% |
| 2023 | 6 | 83.3% |
| 2024 | 11 | 72.7% |
| 2025 | 8 | 62.5% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 14 | 71.4% | 64.2% |
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 13 | 92.3% | 64.2% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 7 | 57.1% | 64.2% |
| Urgent or emergencyThe findings mention urgency. | 3 | 100.0% | 64.2% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement and prospective authorization and coverage for a Zoll LifeVest wearable cardio-defibrillator. The Zoll LifeVest is indicated for newly diagnosed non-ischemic cardiomyopathy with a left ventricular ejection fraction less than or equal to 35% during the initial guideline-directed medical therapy optimization period up to 90 days …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for a Zoll LifeVest wearable cardioverter defibrillator. Per the medical records, the patient has newly diagnosed non-ischemic cardiomyopathy with severe cardiomyopathy. While the data supporting routine use of a LifeVest for all patients is limited, current clinical use supports consideration in selected patients at risk …”
“The physician reviewer found that a patient has requested reimbursement for Zoll LifeVest. Findings: Three of the three reviewers found that the Zoll LifeVest at issue was likely to have been more beneficial for the treatment of the patient's medical condition than any available standard therapy. The Zoll LifeVest is indicated for patients with newly diagnosed severe left ventricular dysfunction …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for Zoll LIfeVest wearable cardioverter defibrillator. The continuation and optimization of heart failure guideline directed medical therapy followed by implantable cardioverter defibrillator (ICD) insertion thereafter if the left ventricular ejection fraction remains less than 35% is considered appropriate and compatible with accepted standard of care …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Wearable Cardio Defib denials for Cardiac/Circ Problem overturned?
In 53 California IMR decisions from 2019 to 2025, reviewers overturned 34 (64.2%). In the last five years: 68.4% of 38. 7 were medical-necessity disputes, 46 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.